You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Dow
Colorcon
Merck
Moodys

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

Valeant Pharms North Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for VALEANT PHARMS NORTH, and what generic alternatives to VALEANT PHARMS NORTH drugs are available?

VALEANT PHARMS NORTH has twenty approved drugs.

There are ten US patents protecting VALEANT PHARMS NORTH drugs.

There are fifty-one patent family members on VALEANT PHARMS NORTH drugs in seventeen countries and thirty-five supplementary protection certificates in fifteen countries.

Summary for Valeant Pharms North
International Patents:51
US Patents:10
Tradenames:17
Ingredients:16
NDAs:20

Drugs and US Patents for Valeant Pharms North

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-002 Apr 23, 2008 RX Yes No 7,645,802   Start Trial Y   Start Trial
Valeant Pharms North APLENZIN bupropion hydrobromide TABLET, EXTENDED RELEASE;ORAL 022108-003 Apr 23, 2008 RX Yes Yes 7,585,897   Start Trial Y   Start Trial
Valeant Pharms North DILTIAZEM HYDROCHLORIDE diltiazem hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 075116-004 Dec 23, 1999 AB3 RX No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Valeant Pharms North

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharms North RETIN-A tretinoin CREAM;TOPICAL 017340-001 Approved Prior to Jan 1, 1982 3,729,568   Start Trial
Valeant Pharms North IPRIVASK desirudin recombinant INJECTABLE;SUBCUTANEOUS 021271-001 Apr 4, 2003 6,103,515   Start Trial
Valeant Pharms North CARAC fluorouracil CREAM;TOPICAL 020985-001 Oct 27, 2000 4,690,825   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for VALEANT PHARMS NORTH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Tablets 348 mg ➤ Subscribe 2009-09-24
➤ Subscribe Extended-release Tablets 174 mg ➤ Subscribe 2009-09-28
➤ Subscribe Extended-release Tablets 522 mg ➤ Subscribe 2009-12-24
➤ Subscribe Cream 0.5% ➤ Subscribe 2011-07-29

Supplementary Protection Certificates for Valeant Pharms North Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 SPC/GB13/061 United Kingdom   Start Trial PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
0328535 96C0021 Belgium   Start Trial PRODUCT NAME: LANSOPRAZOLE + CLARITHROMYCINE + METRONIDAZOLE; REGISTRATION NO/DATE IN FRANCE: K 27 17033R DU 19960209; REGISTRATION NO/DATE AT EEC: K 27 17033R DU 19960209
1304992 2013C/060 Belgium   Start Trial PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Medtronic
Mallinckrodt
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.